Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20370-20387

  Jung, Jaeyun ^a   Yeom, Chanjoo ^b   Choi, Yeon Sook ^b   Kim, Sinae ^a   Lee, EunJi ^a   Park, Min Ji ^a   Kang, Sang Wook ^a   Kim, Sung Bae ^a,b   Chang, Suhwan ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Breast cancer; MiRNA inhibitor; MiRNA sponge; Oncogenic microRNA; Pancreatic cancer

Indexed keywords

DOXORUBICIN; DOXYCYCLINE; MESSENGER RNA; MICRORNA; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 25; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA BINDING; ANIMAL; BREAST TUMOR; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PANCREAS TUMOR; SPONGE (PORIFERA); TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PORIFERA; TRANSFECTION;

EID: 84940211397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4827     Document Type: Article

References (48)

1. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell. 2008; 132:9-14.
2. Georges M, Coppieters W, Charlier C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Current opinion in genetics & development. 2007; 17:166-176.
3. Doxakis E. Principles of miRNA-target regulation in metazoan models. International journal of molecular sciences. 2013; 14:16280-16302.
4. Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Current opinion in cell biology. 2009; 21:452-460.
5. Lai EC. miRNAs: whys and wherefores of miRNA-mediated regulation. Current biology: CB. 2005; 15:R458-460.
6. Wilson JA, Sagan SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Current opinion in virology. 2014; 7:11-18.
7. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic acids research. 2014; 42:609-621.
8. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:6260-6270.
9. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature methods. 2007; 4:721-726.
10. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). International journal of oncology. 2013; 43:985-994.
11. Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods. 2008; 44:55-60.
12. Takahashi M, Yamada N, Hatakeyama H, Murata M, Sato Y, Minakawa N, Harashima H, Matsuda A. In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic acids research. 2013; 41:10659-10667.
13. Lennox KA, Owczarzy R, Thomas DM, Walder JA, Behlke MA. Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Molecular therapy Nucleic acids. 2013; 2:e117.
14. Wu SQ, Xu ZZ, Lin J, Zhan R. Construction of miRNA sponge targeting miR-20a and stable expression in Jurkat leukemia cell line. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = Journal of experimental hematology/Chinese Association of Pathophysiology. 2012; 20:1056-1062.
15. Chen L, Zhang K, Shi Z, Zhang A, Jia Z, Wang G, Pu P, Kang C, Han L. A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncology reports. 2014; 31:1573-1580.
16. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A. Generation of miRNA sponge constructs. Methods (San Diego, Calif). 2012; 58:113-117.
17. Zhu Q, Sun W, Okano K, Chen Y, Zhang N, Maeda T, Palczewski K. Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina. The Journal of biological chemistry. 2011; 286:31749-31760.
18. Dylla L, Jedlicka P. Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One. 2013; 8:e63032.
19. Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z, Zhu Q. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast cancer research: BCR. 2014; 16:473.
20. Shah AA, Leidinger P, Blin N, Meese E. miRNA: small molecules as potential novel biomarkers in cancer. Current medicinal chemistry. 2010; 17:4427-4432.
21. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer gene therapy. 2008; 15:341-355.
22. Previati M, Manfrini M, Galasso M, Zerbinati C, Palatini J, Gasparini P, Volinia S. Next generation analysis of breast cancer genomes for precision medicine. Cancer letters. 2013; 339:1-7.
23. Izumiya M, Tsuchiya N, Okamoto K, Nakagama H. Systematic exploration of cancer-associated microRNA through functional screening assays. Cancer science. 2011; 102:1615-1621.
24. Seddiki N, Brezar V, Ruffin N, Levy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. 2014; 142:32-38.
25. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunological reviews. 2013; 253:146-157.
26. Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, Oveckova I, Chovanec M. miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma. 2014; 61:241-251.
27. Chang S, Sharan SK. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget. 2012; 3:5-6.
28. Kim S, Rhee JK, Yoo HJ, Lee HJ, Lee EJ, Lee JW, Yu JH, Son BH, Gong G, Kim SB, Singh SR, Ahn SH, Chang S. Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer. Cancer letters. 2015; 357:488-497.
29. Indolfi C, Curcio A. Stargazing microRNA maps a new miR-21 star for cardiac hypertrophy. The Journal of clinical investigation. 2014; 124:1896-1898.
30. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X, Chun B, Zhuang J, Zhang C. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovascular research. 2010; 87:431-439.
31. Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochemical Society transactions. 2009; 37:918-925.
32. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA biology. 2011; 8:706-713.
33. Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, Gu M, Lu Q, Yin C. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36:383-391.
34. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. The Journal of biological chemistry. 2007; 282:23716-23724.
35. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Current molecular medicine. 2012; 12:27-33.
36. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell. 2013; 153:654-665.
37. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer research. 1999; 59:2004-2010.
38. Liang WT, Cheng ZY, Jia ZQ, Wang BY. PTEN: a new target in inhibiting of tumor invasion and metastasis. Sheng li ke xue jin zhan [Progress in physiology]. 2011; 42:201-205.
39. Storz P, Doppler H, Copland JA, Simpson KJ, Toker A. FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. Molecular and cellular biology. 2009; 29:4906-4917.
40. Tay FC, Lim JK, Zhu H, Hin LC, Wang S. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Advanced drug delivery reviews. 2015; 81:117-127.
41. Liu Y, Cui H, Wang W, Li L, Wang Z, Yang S, Zhang X. Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. The international journal of biochemistry & cell biology. 2013; 45:2643-2650.
42. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006; 25:6188-6196.
43. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014; 24:R762-776.
44. Bak RO, Hollensen AK, Primo MN, Sorensen CD, Mikkelsen JG. Potent microRNA suppression by RNA Pol II-transcribed 'Tough Decoy' inhibitors. Rna. 2013; 19:280-293.
45. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast cancer research and treatment. 2011; 129:11-21.
46. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. The oncologist. 2011; 16:404-414.
47. Bastian P, Posch B, Lang K, Niggemann B, Zaenker KS, Hatt H, Entschladen F. Phosphatidylinositol 3-kinase in the G protein-coupled receptor-induced chemokinesis and chemotaxis of MDA-MB-468 breast carcinoma cells: a comparison with leukocytes. Molecular cancer research: MCR. 2006; 4:411-421.
48. Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. The Journal of clinical investigation. 2009; 119:3160-3171.